Nycomed Strengthens US Dermatology Business

Nycomed has signed an agreement for the acquisition of Bradley Pharmaceuticals Inc. The acquisition serves to strengthen the Nycomed's dermatology line in US.

Nycomed has announced the entry into a definitive agreement to acquire Bradley Pharmaceuticals, Inc., a company focused on niche therapeutic markets in the USA.

The acquisition will add further branded dermatologics to the PharmaDerm division of Nycomed US and will provide an enhanced platform for in-licensing and co-promotion of dermatology products.

- The acquisition of Bradley provides us with a unique opportunity to strengthen our dermatology expertise in the US with successful products and capabilities that match ours perfectly. The acquisition enables us to gain critical mass in the dermatology market and provides significant momentum for further add-on investments, says Håkan Björklund, CEO of Nycomed.

Purchase price

Bradley Pharmaceutical's Board of Directors has approved the merger agreement. Agreement closure, expected in the first quarter of 2008, is subject to shareholder and antitrust authorities' approval.

Nycomed offers USD 20 per share in cash, or an equity purchase price of USD 346 million to Bradley Pharmaceuticals shareholders.

For further information visit the Nycomed website

Source: Nycomed, press release, 30.10.2007